From the Division of Pediatric Anesthesiology and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland.
Anesth Analg. 2020 Sep;131(3):876-884. doi: 10.1213/ANE.0000000000004509.
Obesity increases susceptibility to chronic pain, increases metabolism, and is associated with obstructive sleep apnea syndrome (OSAS), all which can complicate perioperative pain management of patients. In addition, obesity and OSAS can cause elevation of the adipose-derived hormone leptin, which increases metabolism. We hypothesized that obesity along with sleep apnea and leptin independently enhance morphine pharmacokinetics.
Children 5-12 years of age who were presenting for surgery were administered a morphine dose of 0.05 mg/kg. Blood was collected at baseline and at subsequent preset times for pharmacokinetic analysis of morphine and its metabolites. Three groups were studied: a nonobese group with severe OSAS, an obese group with severe OSAS, and a control group.
Thirty-four patients consisting of controls (n = 16), nonobese/OSAS (n = 8), and obese/OSAS (n = 10) underwent analysis. The obese/OSAS group had a higher dose-adjusted mean maximum morphine concentration (CMAX) over 540 minutes compared to the controls (P < .001) and those with only OSAS (P = .014). The obese/OSAS group also had lower volume of distribution (Vd) when compared to OSAS-only patients (P = .007). In addition, those in the obese/OSAS group had a higher morphine 3-glucuronide (M3G) maximum concentration (P = .012) and a higher ratio of M3G to morphine than did the control group (P = .011). Time to maximum morphine 6-glucuronide (M6G) concentration was significantly lower in both nonobese/OSAS and obese/OSAS groups than in the control group (P < .005). C-reactive protein (CRP), interleukin (IL)-10, and leptin were all higher in the obese/OSAS group than in controls (P = .004, 0.026, and <0.001, respectively), and compared to OSAS-only patients, CRP (P = .013) and leptin (P = .002) levels were higher in the obese/OSAS group.
The combination of obesity and OSAS was associated with an increase in morphine metabolism compared with that in normal-weight controls. Our previous study in mice demonstrated that obesity from leptin deficiency decreased morphine metabolism, but that metabolism normalized after leptin replacement. Leptin may be a cause of the increased morphine metabolism observed in obese patients.
肥胖会增加慢性疼痛的易感性,增加新陈代谢,并与阻塞性睡眠呼吸暂停综合征(OSAS)有关,所有这些都会使患者的围手术期疼痛管理复杂化。此外,肥胖和 OSAS 会导致脂肪衍生激素瘦素升高,从而增加新陈代谢。我们假设肥胖以及睡眠呼吸暂停和瘦素独立地增强了吗啡的药代动力学。
5-12 岁接受手术的儿童给予 0.05mg/kg 的吗啡剂量。在基线和随后的预设时间采集血液,用于吗啡及其代谢物的药代动力学分析。研究了三组:非肥胖伴严重 OSAS 组、肥胖伴严重 OSAS 组和对照组。
34 名患者(对照组 n = 16、非肥胖/OSAS 组 n = 8 和肥胖/OSAS 组 n = 10)进行了分析。与对照组(P <.001)和仅 OSAS 患者(P =.014)相比,肥胖/OSAS 组在 540 分钟内的吗啡平均最高浓度(CMAX)更高。与仅 OSAS 患者相比,肥胖/OSAS 组的分布容积(Vd)也较低(P =.007)。此外,肥胖/OSAS 组的吗啡 3-葡萄糖醛酸(M3G)最高浓度(P =.012)和 M3G 与吗啡的比值也高于对照组(P =.011)。非肥胖/OSAS 和肥胖/OSAS 组的最大吗啡 6-葡萄糖醛酸(M6G)浓度时间明显低于对照组(P <.005)。肥胖/OSAS 组的 C 反应蛋白(CRP)、白细胞介素(IL)-10 和瘦素均高于对照组(P =.004、0.026 和 <0.001),与仅 OSAS 患者相比,肥胖/OSAS 组的 CRP(P =.013)和瘦素(P =.002)水平也更高。
与正常体重对照组相比,肥胖和 OSAS 的结合与吗啡代谢增加有关。我们之前在小鼠中的研究表明,瘦素缺乏引起的肥胖会降低吗啡的代谢,但瘦素替代后代谢恢复正常。瘦素可能是肥胖患者观察到的吗啡代谢增加的原因。